Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in oral drug delivery platforms, announced today that it will attend the BIO International Convention from June 22-25 in San Diego, CA. The company’s attendance at last year’s 2025 BIO convention catalyzed a greatly expanded business development (BD) program that is now delivering positive results, which Lexaria intends to build upon at this year’s conference.
“We are experiencing record-high levels of business development and collaboration interest in our DehydraTECH platform, even before the upcoming BIO conference,” said Richard Christopher, CEO of Lexaria Bioscience. “New business relationships require intense energy and scientific evaluation from both prospective partners to discover the best fit possible. We are working tirelessly in this regard with the intent of generating positive developments that we can publicly discuss.”
BIO is the largest convention of its kind, with over 20,000 attendees expected from all corners of the global pharmaceutical and biotechnology industries, as well as their supporting sectors such as investors and finance professionals. The convention focuses on intra-industry collaborations and meetings, with over 66,000 partnering meetings having taken place at the 2025 conference. Lexaria has already begun reserving meetings and will be fully booked for the event given the strong industry interest in its proprietary DehydraTECH drug delivery platform.
BIO is only the latest example of a multi-faceted BD program that Lexaria quietly launched in order to inform prospective business partners of the benefits available through DehydraTECH. Although confidential information cannot be publicly disclosed, Lexaria’s BD program has already generated a number of collaborative and potential business partnering discussions with a wide range of companies, from innovative smaller biotech developers to well-known global pharmaceutical giants.
While Lexaria’s BD program has already developed a number of ongoing discussions, it continues to develop additional early-stage leads. The company intends to thoroughly evaluate each potential relationship, large and small, and ultimately only pursue those that are in the best interests of its shareholders. Additional information will be made available when appropriate.
Lexaria’s DehydraTECH platform is a patented drug delivery formulation and processing technology that improves the way a wide variety of drugs enter the bloodstream through oral delivery. DehydraTECH has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 65 patents granted and additional patents pending worldwide. For more information, visit www.lexariabioscience.com.
This press release includes forward-looking statements. Such statements are based on current information and involve risks and uncertainties, including market conditions, government regulation, scientific discovery, and the patent application process. Factors that could cause actual results to differ materially include those identified in the company’s public filings with the US Securities and Exchange Commission. The company disclaims any obligation to update forward-looking statements. No statement herein has been evaluated by the FDA. Lexaria-associated products are not intended to diagnose, treat, cure, or prevent any disease.
